The research study is being conducted to test the safety and effectiveness of the
experimental drug mosunetuzumab when given after CAR (genetically modified) T cells. The
study is for patients who have already received a CAR T-cell infusion. Some patients who join
the study will receive mosunetuzumab, other patients later in the study may receive a
different experimental drug (glofitamab).
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania